We report here that BAFF impairs the efficacy of idelalisib, ibrutinib and venetoclax in CLL cells as revealed by analysis of treatment-induced cell death including mitochondria- and caspase-dependent apoptosis. The gene discussed is TNFSF13B; the disease is B-cell chronic lymphocytic leukemia.